請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26554
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林君榮 | |
dc.contributor.author | Kuo-Chen Wu | en |
dc.contributor.author | 吳國禎 | zh_TW |
dc.date.accessioned | 2021-06-08T07:14:59Z | - |
dc.date.copyright | 2008-08-08 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-29 | |
dc.identifier.citation | Abercrombie ED, Finaly JM. Monitoring extracellular norepinephrine in brain using in vivo microdialysis and HPLC-CE. In: Robinson, T.E. (Ed.), Microdialysis in the neuroscience. Elsevier, Amsterdam, 1991, p.253-274.
Alfred H. Schinkel. (1999) P-Glycoprotein, a gatekeeper in the blood–brain barrier. Adv Drug Deliv Rev 36, 179–194. Bakos E, Hegedus T, Hollo Z, Welker E, Tusnady GE, Zaman GJ. (1996) Membrane topology and glycosylation of the human multidrug resistance-associated protein. J Biol Chem 271: 12322–12326. Barakat S, Demeule M, Pilorget A, Régina A, Gingras D, Baggetto LG, Béliveau R. (2007) Modulation of P-glycoprotein function by caveolin-1 phosphorylation. J Neurochem 101: 1-8. Batetta B, Mulas MF, Petruzzo P, Putzolu M, Bonatesta RR, Sanna F, Cappai A, Brotzu G, Dessì S. (2001) Opposite pattern of MDR1 and caveolin-1 gene expression in human atherosclerotic lesions and proliferating human smooth muscle cells. Cell Mol Life Sci 58: 1113-1120. Baxter AG, Cooke A. (1995) The genetics of the NOD mouse Diabetes Metab Rev 11:315-35. Bauser-Heaton HD, Song J, Bohlen HG. (2008) Cerebral microvascular nNOS responds to lowered oxygen tension through a bumetanide-sensitive cotransporter and sodium-calcium exchanger. Am J Physiol Heart Circ Physiol 294: H2166-2173. Bickel PE, Scherer PE, Schnitzer JE, Oh P, Lisanti MP, Lodish HF. (1997) Flotillin and epidermal surface antigen define a new family of caveolae-associated integral membrane proteins. J Biol Chem 272: 13793-13802. Bielschowsky M, Goodall CM. (1970) Origin of inbred NZ mouse strains. Origin of inbred NZ mouse strains. Cancer Res 30: 834-836. Boado RJ, Li JY, Nagaya M, Zhang C, Pardridge WM. (1999) Selective expression of the large neutral amino acid transporter at the blood-brain barrier. Proc Natl Acad Sci USA 96: 12079-12084. Borst P, Elferink RO. (2002) Mammalian ABC transporters in health and disease. Annu Rev Biochem 71: 537-592, 2002. Bredel M. (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Rev 35: 161–204. Brownlee M. (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820. Bucci M, Gratton JP, Rudic RD, Acevedo L, Roviezzo F, Cirino G, and Sessa WC. (2000) In vivo delivery of the caveolin-1 scaffolding domain inhibits nitric oxide synthesis and reduces inflammation. Nat Med 6: 1362–1367. Burant CF, Flink S, DePaoli AM, Chen J, Lee WS, Hediger MA, Buse JB, Chang EB. (1994) Small intestine hexose transport in experimental diabetes. J Clin Invest 93: 578-585. Chang XB. (2007) A molecular understanding of ATP-dependent solute transport by multidrug resistance-associated protein MRP1. Cancer Metastasis Rev 26: 15–37. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesman MM, Roninson IB. (1986) Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47: 381-389. Cohen AW, Razani B, Wang XB, Combs TP, Williams TM, Scherer PE, Lisanti MP. (2003) Caveolin-1 deficient mice show insulin resistance and defective insulin receptor protein expression in adipose tissue. Am J Physiol Cell Physiol 285: C222-C235. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV, Deeley RG. (1992) Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, Bertino JR. (1989) Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 86: 695-698. Dai J, Vrensen G.FJM, Schlingemann RO. (2002) Blood-brain barrier integrity is unaltered in human brain cortex with diabetes mellitus. Brain Res 954: 311-316. Daoud R, Kast C, Gros P, Georges E. (2000) Rhodamine 123 Binds to Multiple Sites in the Multidrug Resistance Protein (MRP1) Biochemistry 39: 15344-15352. de Lange EC, de Boer BA, Breimer DD. (1999) Microdialysis for pharmacokinetic analysis of drug transport to the brain. Adv Drug Deliv Rev 36: 211–227. Demeule M, Jodoin J, Gingras D, Beliveau R. (2000) P-glycoprotein is localized in caveolae in resistant cells and in brain capillaries. FEBS Lett 466: 219-224. Deregowski V, Delhalle S, Benoit V, Bours V, Merville MP. (2002) Identification of cytokine-induced nuclear factor-kappaB target genes in ovarian and breast cancer cells. Biochem Pharmacol 64: 873-881. Dermietzel R, Spray DC, Nedergaard M. Blood-Brain Barrier. From ontogeny to artificial interfaces. 2006, p.431-450. Doms RW. (1990) Oligomerization and protein transport. Methods Enzymol 191: 841-54. Dogan AL, Legrand O, Faussat AM, Perrot JY, Marie JP. (2004) Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk Res 28: 619-622. Dyer J, Wood IS, Palejwala A, Ellis A, Shirazi-Beechey SP. (2002) Expression of monosaccharide transporters in intestine of diabetic humans. Am J Physiol Gastrointest Liver Physiol 282: G241-G248. Ennis SR, Betz AL. (1986) Sucrose permeability of the blood-retinal and blood-brain barriers. Effects of diabetes, hypertonicity, and iodate. Invest Ophthalmol Visual Sci 27: 1095-1102. Fra AM, Masserini M, Palestini P, Sonnino S, Simons K. (1995) A photo-reactive derivative of ganglioside GM1 specifically cross-links VIP21-caveolin on the cell surface. FEBS Lett 375: 11–14. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. (1987) Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84: 265-269. Fujimoto T, Kogo H, Nomura R, Une T. (2000) Isoforms of caveolin-1 and caveolar structure. J Cell Sci 113: 3509-3517. Galbiati F, Volonte D, Brown AM, Weinstein DE, Ben-Ze'ev A, Pestell RG, Lisanti MP. (2000) Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 275: 23368-23377. Gangopadhyay A, Thamotharan M, Adibi SA. (2002) Regulation of oligopeptide transporter (Pept-1) in experimental diabetes. Am J Physiol Gastrointest Liver Physiol 283: G133-G138. García-Cardeña G, Fan R, Stern DF, Liu J, Sessa WC. (1996) Endothelial nitric oxide synthase is regulated by tyrosine phosphorylation and interacts with caveolin-1. J Biol Chem 271: 27237-27240. Georges E, Tsuruo T, Ling V. (1993) Topology of P-glycoprotein as determined by epitope mapping of MRK-16 monoclonal antibody. J Biol Chem 268: 1792-1798. Gottesman MM, Fojo T, Bates SE. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2: 48-58. Gottesman MM, Hrycyna CA, Schoenlein PV, Germann UA, Pastan I. (1995) Genetic analysis of the multidrug transporter. Annu Rev Genet 29: 607-649. Grillo CA, Piroli GG, Rosell DR, Hoskin EK, Mcewen BS, Reagan LP. (2003) Region specific increases in oxidative stress and superoxide dismutase in the hippocampus of diabetic rats subjected to stress. Neuroscience 121: 133-140. Gros P, Raymond M, Bell J, Housman D. (1988) Cloning and characterization of a second member of the mouse mdr gene family. Mol Cell Biol 8: 2770-2778. Haimeur A, Conseil G, Deeley RG, Cole SP. (2004) The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5: 21-53. Hayashi T, Juliet PA, Miyazaki A, Ignarro LJ, Iguchi A. (2007) High glucose downregulates the number of caveolae in monocytes through oxidative stress from NADPH oxidase: implications for atherosclerosis. Biochim Biophys Acta 1772: 364-372. Higgins CF. (1992) ABC transporters: from microorganisms to man. Annu Rev Cell Biol 8: 67-113. Hotamisligil G.S, Budavari A, Murray D, Spiegelman BM. (1994) Reduced tyrosine kinase activity on the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-α. J Clin Invest 94: 1543-1549. Inukai T, Takanashi K, Tayama K, Aso Y, Takemura Y. (2002) High glucose concentrations abolish the superoxide dismutase response of leukocytes to ascorbic acid or troglitazone in type 2 diabetes mellitus. Life Sci 70: 2391-2401. Ishikawa T. (1992) The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci. 17: 463-468. Jakobsen J, Sidenius P, Gundersen HJ, Osterby R. (1987) Quantitative changes of cerebral neocortical structure in insulin-treated long-term streptozocin-induced diabetes in rats. Diabetes 36: 597-601. Jetté L, Potier M, Béliveau R. (1997) P-glycoprotein is a dimer in the kidney and brain capillary membranes: effect of cyclosporin A and SDZ-PSC 833. Biochemistry 36: 13929-13937. Jodoin J, Demeule M, Fenart M, Cecchelli L, Farmer S, Linton KJ, Higgins CF, Beliveau R. (2003) P-glycoprotein in blood-brain barrier endothelial cells: interaction and oligomerization with caveolins. J Neurochem 87: 1010-1023. Juliano RL, Ling VA. (1976) A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455: 152-162. Kamei J, Hirano S, Miyata S, Saitoh A, Onodera K. (2005) Effects of first- and second-generation histamine-H1-receptor antagonists on the pentobarbital- induced loss of the righting reflex in streptozotocin-induced diabetic mice. J Pharmacol Sci 97: 266-272. Koleske AJ, Baltimore D, Lisanti MP. (1995) Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA 92: 1381–1385. Komers R, Schutzer WE, Reed JF, Lindsley JN, Oyama TT, Buck DC, Mader SL, Anderson S. (2006) Altered endothelial nitric oxide synthase targeting and conformation and caveolin-1 expression in the diabetic kidney. Diabetes 55: 1651-1659. Kumagai AK, Kang YS, Boado RJ, Pardridge WM. (1995) Upregulation of blood-brain barrier GLUT1 glucose transporter protein and mRNA in experimental chronic hypoglycemia. Diabetes 44: 1399-1404. Kwak JO, Kim HW, Oh KJ, Kim DS, Han KO, Cha SH. (2005) Co-localization and interaction of organic anion transporter 1 with caveolin-2 in rat kidney. Exp Mol Med 37: 204-212. Kwak JO, Kim HW, Song JH, Kim MJ, Park HS, Hyun DK, Kim DS, Cha SH. (2005) Evidence for rat organic anion transporter 3 association with caveolin-1 in rat kidney. IUBMB Life 57: 109-117. Lam TY, Seto SW, Lau YM, Au LS, Kwan YW, Ngai SM, Tsui KW. (2006) Impairment of the vascular relaxation and differential expression of caveolin-1 of the aorta of diabetic +db/+db mice. Eur J Pharmacol 546: 134-141. Lee G, Bendayan R. (2004) Functional expression and localization of P-glycoprotein in the central nervous system: relevance to the pathogenesis and treatment of neurological disorders. Pharm Res 21: 1313-1324. Leiter EH. (2005) Nonobese diabetic mice and the genetics of diabetes susceptibility. Curr Diab Rep 5: 141-148. Leiter EH, Reifsnyder PC, Flurkey K, Partke HJ, Junger E, Herberg L. (1998) NIDDM genes in mice. Deleterious synergism by both parental genomes contributes to diabetogenic thresholds. Diabetes 47: 1287-1295. Leslie EM, Deeley RG, Cole SPC. (2005) Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 204: 216– 237. Lisanti MP, Scherer PE, Vidugiriene J, Tang Z, Hermanowski-Vosatka A, Tu YH, Cook RF, Sargiacomo M. (1994) Characterization of caveolin-rich membrane domains isolated from an endothelial-rich source: implications for human disease. J Cell Biol 126: 111-126. Lin YC, Ma C, Hsu WC, Lo HF, Yang VC. (2007) Molecular interaction between caveolin-1 and ABCA1 on high-density lipoprotein-mediated cholesterol efflux in aortic endothelial cells. Cardiovasc Res 75: 575-583. Liu H, Zu Z, Yang Z, Deng Y, Liu X, Xie L. (2006) Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats. Brain Res 1123: 245-252. Loo TW, Clarke DM. (1996) The minimum functional unit of human P-glycoprotein appears to be a monomer. J Biol Chem 271: 27488-27492. Lorenzi M, Healy DP, Hawkins R, Printz JM, Printz MP. (1986) Studies of the permeability of the blood-brain barrier in experimental diabetes. Diabetologia 29: 58-62. Loscher W, Potschka H. (2005) Drug resistance in brain diseases and the role of drug efflux transporters. Nat rev neurosci 6: 591-602. Macaulay S, Larkins R. (1988) Impaired Insulin Action in Adipocytes of New Zealand Obese Mice: A Role for Postbinding Defects in Pyruvate Dehydrogenase and Insulin Mediator Activity. Metabolism 37: 958-965. Maeng HJ, Kim MH, Jin HE, Shin SM, Tsuruo T, Kim SG, Kim DD, Shim CK, Chung SJ. (2007) Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab Dispos 35:1996-2005. Marbeuf-Gueye C, Stierle V, Sudwan P, Salerno M, Garnier-Suillerot A. (2007) Perturbation of membrane microdomains in GLC4 multidrug-resistant lung cancer cells modification of ABCC1 (MRP1) localization and functionality. FEBS J 274: 1470–1480. Makar TK, Rimpel-Lamhaouar K, Abraham DG, Gokhale VS, Cooper AJ. (1995) Antioxidant defense systems in the brains of type II diabetic mice. J Neurochem 65: 287-291. Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, and Keppler D. (1995) Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J Cell Biol 131: 137–150. Minami M, Jin KL, Li W, Nagayama T, Henshall DC, Simon RP. (2000) Bcl-w expression is increased in brain regions affected by focal cerebral ischemia in the rat. Neurosci Lett 279: 193-195. Misra A, Ganesh S, Shahiwala A. (2003) Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 6:252-273. Mooradian AD. (1997) Central nervous system complications of diabetes mellitus-a perspective from the blood-brain barrier. Brain Res Rev 23: 210-218. Mooradian AD. (1997) Pathophysiology of central nervous system complications in diabetes mellitus. Clin Neurosci 4: 322-326. Mora R, Bonilha VL, Marmorstein A, Scherer PE, Brown D, Lisanti MP, Rodriguez-Boulan E. (1999) Caveolin-2 localizes to the golgi complex but redistributes to plasma membrane, caveolae, and rafts when co-expressed with caveolin-1. J Biol Chem 274: 25708-25717. Murata M, Peranen J, Schreiner R, Weiland F, Kurzchalia T, Simons K. (1995) VIP21/caveolin is a cholesterol-binding protein. Proc Natl Acad Sci USA 92: 10339–10343. Naito M, Tsuruo T. (1992) Functionally active homodimer of P-glycoprotein in multidrug-resistant tumor cells. Biochem Biophys Res Commun 185: 284-290. Ng WF, Sarangi F, Zastawny RL, Veinot-Drebot L, Ling V. (1989) Identification of members of the P-glycoprotein multigene family. Mol Cell Biol 9: 1224-1232. Oka N, Yamamoto M, Schwencke C, Kawabe J, Ebina T, Ohno S, Couet J, Lisanti MP, Ishikawa Y. (1997) Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide. J Biol Chem 272: 33416-33421. Palade GE. (1953) Fine structure of blood capillaries. J appl physiol 24: 1424-1436. Pandey GN, Dwivedi Y, Ren X, Rizavi HS, Mondal AC, Shukla PK, Conley RR. (2005) Brain region specific alterations in the protein and mRNA levels of protein kinase A subunits in the post-mortem brain of teenage suicide victims. Neuropsychopharmacology. 30: 1548-1556. Pang A, Au WY, Kwong YL. (2004) Caveolin-1 gene is coordinately regulated with the multidrug resistance 1 gene in normal and leukemic bone marrow. Leuk Res 28: 973-977. Pardridge WM, Triguero D, Farrell CR. (1990) Down regulation of blood-brain barrier glucose transporter in experimental diabetes. Diabetes 39: 1040-1044. Parr RD, Martin GG, Hostetler HA, Schroeder ME, Mir KD, Kier AB, Ball JM, Schroeder F. (2007) A new N-terminal recognition domain in caveolin-1 interacts with sterol carrier protein-2 (SCP-2). Biochemistry 46: 8301-8314. Pascariu M, Bendayan M, Ghitescu L. (2004) Correlated endothelial caveolin overexpression and increased transcytosis in experimental diabetes. J Histochem Cytochem 52: 65-76. Paxinos G., Franklin KBJ. The mouse brain in stereotaxic coordinates, second ed. Elsevier, Academic Press, San Diego, CA, 2004. Pei QL, Kobayashi Y, Tanaka Y, Taguchi Y, Higuchi K, Kaito M, Ma N, Semba R, Kamisako T, Adachi Y. (2002) Increased expression of multidrug resistanceassociated protein 1 (mrp1) in hepatocyte basolateral membrane and renal tubular epithelia after bile duct ligation in rats. Hepatol Res 22: 58–64. Peng KC, Cluzeaud F, Bens M, Van Huyen JP, Wioland MA, Lacave R, Vandewalle A. (1999) Tissue and cell distribution of the multidrug resistance-associated protein (MRP) in mouse intestine and kidney. J Histochem Cytochem 47: 757–768. Poruchynsky MS, Ling V. (1994) Detection of oligomeric and monomeric forms of P-glycoprotein in multidrug resistant cells. Biochemistry 33: 4163-4174. Rauch MC, Ocampo ME, Bohle J, Amthauer R, Yáñez AJ, Rodríguez-Gil JE, Slebe JC, Reyes JG, Concha II. (2006) Hexose transporters GLUT1 and GLUT3 are colocalized with hexokinase I in caveolae microdomains of rat spermatogenic cells. J Cell Physiol 207: 397-406. Razani B, Woodman SE, Lisanti MP. (2002) Caveolae: From Cell Biology to Animal Physiology. Pharmacol Rev 54: 431–467. Rechthand E, Smith Q, Latker C, Rapoport SI. (1987) Altered blood-nerve barrier permeability to small molecules in experimental diabetes mellitus. J Neuropath Exp Neurol 46: 302–314. Regina A, Koman A, Piciotti M, El Hafny B, Center MS, Bergmann R, Couraud PO, Roux F. (1998) Mrp1 multidrug resistance-associated protein and P-glycoprotein expression in rat brain microvessel endothelial cells. J Neurochem 71: 705–715. Régina A, Romero IA, Greenwood J, Adamson P, Bourre JM, Couraud PO, Roux F. (1999) Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem 73: 1954-1963. Reifsnyder PC, Leiter EH. (2002) Deconstructing and reconstructing obesity-induced diabetes (diabesity) in mice. Diabetes 51: 825-832. Renes J, de Vries EG, Nienhuis EF, Jansen PL, Muller M. (1999) ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. Br J Pharmacol 126: 681–688. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. (1992) Caveolin, a protein component of caveolae membrane coats. Cell 68: 673–682. Saengkhae C, Loetchutinat C, Garnier-Suillerot A. (2003) Kinetic Analysis of Rhodamines Efflux Mediated by the Multidrug Resistance Protein (MRP1). Biophys J 85: 2006–2014. Sargiacomo M, Scherer PE, Tang ZL, Casanova JE, Lisanti MP. (1994) In vitro phosphorylation of caveolin-rich membrane domains: identification of an associated serine kinase activity as a casein kinase II-like enzyme. Oncogene 9: 2589-2595. Sargiacomo M, Sudol M, Tang Z, Lisanti MP. (1993) Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J Cell Biol 122: 789-807. Schägger H, von Jagow G. (1991) Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form. Anal Biochem 199: 223-231. Scherer PE, Okamoto T, Chun M, Nishimoto I, Lodish HF, and Lisanti MP. (1996) Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci USA 93: 131–135. Scherer PE, Lisanti MP, Baldini G, Sargiacomo M, Corley-Mastick C, Lodish HF. (1994) Induction of caveolin during adipogenesis and association of GLUT4 with caveolin-rich vesicles. J Cell Biol 127:1233–1243. Seetharaman S, Barrand MA, Maskell L, Scheper RJ. (1998) Multidrug resistance-related transport proteins in isolated human brain microvessels and in cells cultured from these isolates. J Neurochem 70: 1151–1159. Sima AAF, Shafrir E. Animal Models of Diabetes: A Primer. Amsterdam: Harwood Academic Publishers, 2000. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E. (1993) Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451–462. Smyth S, Heron A. (2006) Diabetes and obesity: the twin epidemics. Nat Med 12: 75 – 80. Stauber WT, Ong SH, McCuskey RS. (1981) Selective extravascular escape of albumin into the cerebral cortex of the diabetic rat. Diabetes 30: 500-503. Storch CH, Ehehalt R, Haefeli WE, Weiss J. (2007) Localization of the human breast cancer resistance protein (BCRP/ABCG2) in lipid rafts/caveolae and modulation of its activity by cholesterol in vitro. J Pharmacol Exp Ther 323: 257-264. Swamy M, Siegers GM, Minguet S, Wollscheid B, Schamel WW. (2006) Blue native polyacrylamide gel electrophoresis (BN-PAGE) for the identification and analysis of multiprotein complexes. Sci STKE 2006: pl4-p30. Tan W, Rouen S, Barkus KM, Dremina YS, Hui D, Christianson JA, Wright DE, Yoon SO, Dobrowsky RT. (2003) Nerve growth factor blocks the glucose-induced down-regulation of caveolin-1 expression in Schwann cells via p75 neurotrophin receptor signaling. J Biol Chem 278: 23151-23162. Tang ZL, Scherer PE, Okamoto T, Song K, Chu C, Kohtz DS, Nishimoto I, Lodish HF, Lisanti MP. (1996) Molecular cloning of caveolin-3, a novel member of the caveolin gene family expressed predominantly in muscle. J Biol Chem 271: 2255–2261. Taylor JC, Horvath AR, Higgins CF, Begley GS. (2001) The multidrug resistance P-glycoprotein. Oligomeric state and intramolecular interaction. J Biol Chem 276: 36075-36078. Troost J, Lindenmaier H, Haefeli WE, Weiss J. (2004) Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells. Mol Pharmacol 66: 1332-1339. van der Bliek AM, Kooiman PM, Schneider C, Borst P. (1988) Sequence of mdr3 cDNA encoding a human P-glycoprotein. Gene 71: 401-411. Way M, Parton R. (1995) M-caveolin, a muscle-specific caveolin-related protein. FEBS Lett 376: 108–112. Yamamoto M, Toya Y, Schwencke C, Lisanti MP, Myers MG Jr, Ishikawa Y. (1998) Caveolin is an activator of insulin receptor signaling. J Biol Chem 273: 26962-26968. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. (1999) Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayers in the presence of cytochrome P-450 3A-related compounds. J Pharmacol Exp Ther 289: 149-155. Yunomae K, Arima H, Hirayama F, Uekama K. (2003) Involvement of cholesterol in the inhibitory effect of dimethyl-beta-cyclodextrin on P-glycoprotein and MRP2 function in Caco-2 cells. FEBS Lett 536: 225-231. Zhou G, Kuo MT. (1997) NF-κB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272: 15174-15183. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26554 | - |
dc.description.abstract | 糖尿病是一種全身性的代謝疾病,可能造成視網膜、腎臟、神經和血管方面的病變。近來有研究指出糖尿病可能改變腦部的血流和血腦障壁間物質的運送,P-glycoprotein (P-gp, MDR1) 表現在腦部微血管上的luminal side,並且分布在caveolae上,主要功能是排除其受質並保護腦部組織。本研究主要是探討在糖尿病的情形下,caveolin-1與caveolin-2的蛋白質表現量和P-gp功能的關係;在第二部分的研究中,我們探討糖尿病是否影響P-gp的寡聚化。
本研究所使用的自發性第一型和第二型糖尿病動物模式分別為NOD (non-obese diabetic) 和NZO (New Zealand obese) 小鼠,對照組則是NON (non-obese, non-diabetic) 小鼠。西方墨點法的結果顯示NZO公鼠腦中P-gp的表現量大約是NON公鼠的1.5倍,而NOD母鼠的P-gp表現量則是有些微的降低。組織免疫染色的結果顯示NZO公鼠腦部微血管上P-gp表現量上升,而NOD母鼠腦部微血管上P-gp表現量沒有顯著的改變。雖然西方墨點法的結果顯示NOD母鼠和NZO公鼠腦中caveolin-1和caveolin-2的蛋白質表現量都上升,但是在組織免疫染色中,NOD母鼠和NZO公鼠大腦紋狀體微血管上caveolin-1和caveolin-2的蛋白質表現量反而是下降的。我們選用P-gp典型的受質rhodamine 123從靜脈給藥並利用體內大腦微透析系統 (in vivo brain microdialysis technique) 來分析P-gp在血腦障壁上排除受質的能力,結果發現在NOD母鼠和NZO公鼠腦細胞外液中藥物濃度大約只有NON小鼠的一半,顯示糖尿病小鼠腦中P-gp的功能是增加的。 在第二部分的研究中,我們利用blue native polyacrylamide gel電泳 (BN-PAGE) 合併西方墨點法來分析自然型態的P-gp,結果顯示在NON小鼠腦中的P-gp是以二聚體的型態存在,但是在NOD公鼠、NOD母鼠和NZO公鼠腦中,P-gp會形成單體及二聚體。 糖尿病小鼠腦部微血管上P-gp的功能除了蛋白質本身表現量的影響之外,caveolin-1和caveolin-2蛋白質的表現量也扮演重要調控的角色;另外,糖尿病也可能改變P-gp在腦中的寡聚化,不過P-gp聚合的程度在生理上的意義為何仍需進一步的研究。綜合以上的實驗結果,我們發現不管是在自發性第一型糖尿病或是第二型糖尿病小鼠大腦微血管上,P-gp的功能都有顯著的增加。 | zh_TW |
dc.description.abstract | Diabetes mellitus is a systematic metabolic disease and is related to a number of complications, including retinopathy, nephropathy, neuropathy, and vascular diseases. Recent studies show that diabetic pathology may alter cerebral blood flow and blood brain transport. P-glycoprotein (P-gp, MDR1) is highly expressed in the luminal side of brain capillary and is located in the caveolae. The current study is to investigate brain expression of caveolin-1 and caveolin-2, the major proteins of caveolae, and P-gp function in diabetes. On the other hand, this study is also to investigate P-gp oligomer formation in diabetes.
Inbred non-obese diabetic (NOD) and New Zealand obese (NZO) mice were used as the models of type 1 and type 2 diabetes, respectively, in comparison with non-obese non-diabetic (NON) mice. Western blots showed that P-gp protein expression was significantly higher (about 1.5-fold) in the brain of male NZO mice and slightly lower in the brain of female NOD mice than in male and female NON mice. Immunohistochemical staining showed higher P-gp expression in the brain capillaries of male NZO mice, whereas expression in female NOD mice was comparable to that in NON mice. Although levels of caveolin-1 and caveolin-2 were significantly higher in the brain of female NOD and male NZO mice on Western blots, immunochemical analysis showed lower caveolin expression in the capillaries in brain striatum of female NOD and male NZO mice compared to NON mice of the same gender. P-gp efflux pump activity in the blood-brain barrier (BBB) was measured by an in vivo brain microdialysis technique. Brain extracellular concentrations of intravenously injected rhodamine 123, a known P-gp substrate, were decreased by half in female NOD and male NZO mice, showing higher P-gp efflux pump activity. To investigate P-gp oligomerization, blue native polyacrylamide gel electrophoresis (BN-PAGE) was used to separate native forms of P-gp. P-gp exists as a dimer in the brain of male and female NON mice. However, mono- and dimeric forms of P-gp were both detected in the brain of male and female NOD and male NZO mice. In conclusion, P-gp activity in brain capillaries in diabetic mice is not only due to P-gp protein expression, but may also be affected by caveolin expression. On the other hand, P-gp oligomeric formation may be affected by diabetes, and further studies are still required to understand the physiological role of P-gp multimerization. Inbred mice with type 1 or type 2 diabetes show increased P-gp activity in the blood-brain barrier. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:14:59Z (GMT). No. of bitstreams: 1 ntu-97-R95423001-1.pdf: 42953558 bytes, checksum: 24b27087f68ce0f60dd381a3a4a14f0e (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | Abstract i
中文摘要 iii 目錄 v 圖目錄 ix 表目錄 xi 第1章 文獻回顧 1 1.1. 糖尿病 (Diabetes Mellitus) 1 1.1.1. 糖尿病簡介 1 1.1.2. 人類糖尿病動物模式 2 1.2. 血腦障壁 (Blood-brain barrier, BBB) 5 1.3. ATP binding cassette transporters 6 1.3.1. P-glycoprotein (P-gp, MDR1) 6 1.3.2. Multidrug resistance-associated protein 1 (MRP1) 8 1.4. Caveolae and caveolins 10 1.5. 實驗系統 12 1.5.1. 微透析系統 (Microdialysis system) 12 1.5.2. BN-PAGE (Blue native polyacrylamide gel electrophoresis) 13 第2章 研究目的 15 第3章 實驗材料 16 3.1. 實驗動物 16 3.2. 血糖監測試驗 16 3.3. 微透析試驗 16 3.4. 高效能液相層析試驗 17 3.5. 膠體電泳及西方墨點法 18 3.6. 免疫組織化學染色 19 3.7. 溶液配方 20 第4章 實驗方法 23 4.1. 實驗動物血糖監測 23 4.2. P-glycoprotein在血腦障壁通透量之研究 23 4.2.1. 大腦微透析探針製備方法 23 4.2.2. 探針回收率 (Recovery) 體外試驗 24 4.2.3. 小鼠大腦立體定位手術 24 4.2.4. 大腦微透析系統體內試驗 25 4.2.5. 高效能液相層析法與螢光偵測法 25 4.3. 腦部膜蛋白質萃取 26 4.4. 腦部細胞溶解液萃取 26 4.5. 蛋白質濃度測定 26 4.5.1. Bio-Rad Bradford protein assay 27 4.5.2. Bio-Rad DC protein assay 27 4.6. 腦部蛋白質表現量分析 27 4.6.1. SDS-PAGE配置與電泳 28 4.6.2. SDS-PAGE蛋白質轉漬與西方墨點法 28 4.7. 免疫組織化學染色 29 4.7.1. 福馬林灌流 29 4.7.2. 石蠟包埋 30 4.7.3. 玻片鍍膜 30 4.7.4. 切片與貼片 31 4.7.5. 免疫組織化學染色 31 4.7.6. 蘇木精染色 32 4.7.7. 封片與攝影 32 4.8. P-gp 寡聚化 (oligomerization) 分析 33 4.8.1. 樣本萃取 33 4.8.2. BN-PAGE膠片配置與電泳 33 4.8.3. BN-PAGE蛋白質轉漬與西方墨點法 34 4.9. 統計分析 35 第5章 實驗結果 36 5.1. 小鼠生理數據監測 36 5.1.1. 年齡 36 5.1.2. 體重監測 36 5.1.3. 血糖監測 36 5.2. 糖尿病影響P-gp功能之研究 36 5.2.1. 空白液試驗 36 5.2.2. Rhodamine 123定量試驗 37 5.2.3. 糖尿病小鼠腦中藥物濃度之研究 37 5.3. 糖尿病影響腦部特定蛋白表現量之研究 38 5.3.1. 糖尿病影響腦部P-gp蛋白質表現量之研究 38 5.3.2. 糖尿病影響腦部caveolin-1蛋白質表現量之研究 38 5.3.3. 糖尿病影響腦部caveolin-2蛋白質表現量之研究 39 5.3.4. 糖尿病影響腦部MRP1蛋白質表現量之研究 39 5.3.5. 糖尿病影響腦部phosphocaveolin-1蛋白質表現量之研究 40 5.4. 糖尿病影響腦部微血管上特定蛋白質表現量之研究 40 5.4.1. 糖尿病影響P-gp在紋狀體微血管上表現量之研究 40 5.4.2. 糖尿病影響caveolin-1在紋狀體微血管上表現量之研究 40 5.4.3. 糖尿病影響caveolin-2在紋狀體微血管上表現量之研究 41 5.4.4. 糖尿病影響P-gp在其他腦區微血管上表現量之研究 41 5.4.5. 糖尿病影響caveolin-1在其他腦區微血管上表現量之研究 41 5.4.6. 糖尿病影響caveolin-2在其他腦區微血管上表現量之研究 41 5.5. 糖尿病影響腦部P-glycoprotein寡聚化之研究 42 第6章 結果討論 68 6.1. 糖尿病影響血腦障壁之探討 68 6.2. 糖尿病影響P-gp功能之探討 69 6.3. 糖尿病影響P-gp表現量之探討 69 6.4. 糖尿病影響Caveolin表現量之探討 71 6.5. Caveolin表現量影響P-gp功能之探討 72 6.6. 糖尿病影響MRP1表現量及功能之探討 74 6.7. 糖尿病影響P-glycoprotein寡聚化 (oligomerization) 之探討 75 第7章 結論 78 第8章 參考文獻 79 附錄 95 | |
dc.language.iso | zh-TW | |
dc.title | P-glycoprotein在第一型及第二型糖尿病小鼠大腦微血管上表現量及功能之探討 | zh_TW |
dc.title | P-glycoprotein expression and function in brain capillaries of inbred mice with type 1 or type 2 diabetes | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 陳美如,潘慧如,尹相姝,劉宏輝 | |
dc.subject.keyword | P-glycoprotein,血腦障壁,糖尿病, | zh_TW |
dc.subject.keyword | P-glycoprotein,blood-brain barrier,diabetes, | en |
dc.relation.page | 106 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-30 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥學研究所 | zh_TW |
顯示於系所單位: | 藥學系 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 41.95 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。